Epidemiological aspects of irritable bowel syndrome in Europe and North America

被引：72

作者：

Müller-Lissner, SA

Bollani, S

Brummer, RJ

Coremans, G

Dapoigny, M

Marshall, JK

Muris, JWM

Wolthuis, AOK

Pace, F

Rodrigo, L

Stockbrügger, R

Vatn, MH

机构：

[1] Charite, Lehrkrankenhaus, Pk Klin Weissensee, Innere Med Abt, D-13086 Berlin, Germany

[2] Osped L Sacco, Milan, Italy

[3] Univ Hosp, Maastricht, Netherlands

[4] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium

[5] Hop Hotel Dieu, Clermont Ferrand, France

[6] McMaster Univ, Hamilton, ON, Canada

[7] Univ Maastricht, Dept Gen Practice, Maastricht, Netherlands

[8] Univ Hosp, Oviedo, Spain

[9] Rikshosp Univ Hosp, Oslo, Norway

来源：

DIGESTION | 2001年 / 64卷 / 03期

关键词：

irritable bowel syndrome; epidemiology; prevalence; reporter; consulter;

D O I：

10.1159/000048862

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

The epidemiology of irritable bowel syndrome (IBS) in Europe and North America was analyzed from published material. The percentage of the population of Western civilisation with IBS symptoms is between 10 and 15% in most studies. The proportion of a Western population visiting a doctor for IBS symptoms is around 5%. The prevalence of IBS and the proportion of consulters do not seem to depend on age in an adult population. The female-to-male ratio of IBS in the population is close to 2. It is higher in IBS consulters in primary care and may be as high as 3 or 4 in tertiary referral centers. At least in patients from these centers, the number of physician visits and colonoscopies is considerable. Most of the consulters get a drug prescription. Copyright (C) 2001 S. Karger AG, Basel.

引用

页码：200 / 204

页数：5

共 33 条

[21]

METMAN EH, 1980, GASTROEN CLIN BIOL, V4, P858

[22] Tegaserod, a 5-HT4 receptor partial agonist, relieves key symptoms of irritable bowel syndrome (IBS). [J].